Source: Washington Post
Emergent BioSolutions plans to expand its operations in order to provide large-scale production of its BioThrax anthrax vaccine. The Rockville, Md., based company will open a new facility in Lansing, Mich., to help meet its goal of protecting U.S. military personnel against the biological weapons threat. The U.S. government has ordered 44.8 million doses of BioThrax anthrax vaccine in an agreement worth as much as $1.25 billion over five years. Emergent BioSolutions says it could take until 2014 or 2015 for the new facility to complete a review by the U.S. Food and Drug Administration and receive certification.